News and Events
News and Events
You may sort news and events by title or recency. If you wish to view only news, please select the news link from the left. If you wish to see events at which Quintiles is scheduled to participate, please select the events link from the left.
- Sort by: Most Recent
- Title
-
QUINTILES REPORTS 3rd QUARTER NET REVENUE OF $470.3 MILLION, UP 19%
November 14, 2005 – Quintiles Transnational Corp. today announced financial results for the quarter ended September 30, 2005. Net revenue for third quarter 2005 was $470.3 million, an increase of 19% from net revenue of $396.5 million for third quarter 2004. Profit contribution from Quintiles' Product Development and Commercial Services groups totaled $210.5 million in third quarter 2005, up from $193.1 million for third quarter 2004. -
QUINTILES TRANSNATIONAL ANNOUNCES LIVE WEBCAST FOR THIRD QUARTER EARNINGS
November 10, 2005 – Quintiles Transnational Corp. today announced that it will conduct a live webcast of its third quarter 2005 earnings release conference call on Tuesday, Nov. 15, at 11:00 a.m. EST. -
QUINTILES COMPLETES AGREEMENT WITH APTUIT
Sept. 30, 2005 – Quintiles Transnational Corp. today announced the completion of the previously announced agreement with Aptuit, Inc., to enter a strategic partnership. -
QUINTILES SUBSIDIARY TO PRIVATELY OFFER DULOXETINE SECURED NOTES
August 19, 2005 – Quintiles Transnational Corp. today announced that its newly formed subsidiary, Duloxetine Royalty Sub (“Royalty Sub”), intends to issue $150 million of Duloxetine Secured Notes, plus as much as $50 million to $150 million of additional notes, depending on market and other conditions. Quintiles expects to use the net proceeds it will receive from Royalty Sub to repay in full all outstanding term loans, if any, under Quintiles’ existing senior secured credit facility, for any other purposes permitted under Quintiles’ other debt arrangements and for general corporate purposes. -
QUINTILES REPORTS 2nd QUARTER NET REVENUE OF $537 MILLION, UP 26 PERCENT
August 12, 2005 – Quintiles Transnational Corp. today announced financial results for the quarter ended June 30, 2005. Net revenue for second quarter 2005 was $537.4 million, an increase of 26% from net revenue of $425.8 million for second quarter 2004. Contribution from Quintiles' Product Development and Commercial Services groups totaled $243.0 million in second quarter 2005, up 28% from $189.7 million for second quarter 2004. -
QUINTILES TRANSNATIONAL ANNOUNCES LIVE WEBCAST FOR SECOND QUARTER EARNINGS
August 9, 2005 – Quintiles Transnational Corp. today announced that it will conduct a live webcast of its second quarter 2005 earnings release conference call on Friday, Aug. 12, at 1:00 p.m. EDT. -
FDA LEADER JOINS QUINTILES' REGULATORY GROUP
August 2, 2005 – Quintiles Transnational Corp. today announced the appointment of an expert in the regulation of pharmaceutical and biotechnology products, Edward Tabor, M.D., as Executive Director, Regulatory & Technical Services. -
KIYOTAKA FUJII APPOINTED PRESIDENT AND CHIEF EXECUTIVE OFFICER OF QUINTILES JAPAN
July 21, 2005 – Quintiles Transnational Corp. today announced the appointment of Kiyotaka Fujii as President and Chief Executive Officer of Quintiles Transnational Japan K.K. (Quintiles Japan) as of August 1, 2005. -
QUINTILES, APTUIT TO FORM STRATEGIC ALLIANCE FOR EARLY DRUG DEVELOPMENT
July 19, 2005 – Quintiles Transnational Corp., the world's leading pharmaceutical services organization, announced today that it has signed an agreement with Aptuit Inc., an emerging company focused on streamlining and supporting the early drug development process, to enter a strategic partnership. Aptuit will acquire three Quintiles business units – Preclinical Services, Pharmaceutical Sciences and Clinical Trial Supplies – for approximately $125 million, and the two companies will sign a two-year commercial agreement. -
INTERPHARMA, QUINTILES AND TEMASEK TO FORM JOINT VENTURE
June 9, 2005 – Three global companies have announced a joint venture to commercialize pharmaceutical products in the Asia Pacific region. Partners in the joint venture, which will have an investment fund totaling US$112 million, include leading Asia Pacific pharmaceutical services group, Interpharma Asia Pacific, parent of drug distributor Zuellig Pharma; Asia investment company Temasek Holdings (Private) Limited; and Quintiles Transnational Corp., the world's leading pharmaceutical services organization, who has signed a letter of intent to join the venture. Each partner is expected to make an equal investment in the joint venture and own one-third each of the company.